BR112021009653A2 - método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico - Google Patents

método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico Download PDF

Info

Publication number
BR112021009653A2
BR112021009653A2 BR112021009653-1A BR112021009653A BR112021009653A2 BR 112021009653 A2 BR112021009653 A2 BR 112021009653A2 BR 112021009653 A BR112021009653 A BR 112021009653A BR 112021009653 A2 BR112021009653 A2 BR 112021009653A2
Authority
BR
Brazil
Prior art keywords
corticosteroid
dose
urine
hsd1 inhibitor
patient
Prior art date
Application number
BR112021009653-1A
Other languages
English (en)
Portuguese (pt)
Inventor
David A. Katz
Original Assignee
Sparrow Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sparrow Pharmaceuticals, Inc. filed Critical Sparrow Pharmaceuticals, Inc.
Publication of BR112021009653A2 publication Critical patent/BR112021009653A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021009653-1A 2018-11-20 2019-08-14 método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico BR112021009653A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
US62/769,932 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Publications (1)

Publication Number Publication Date
BR112021009653A2 true BR112021009653A2 (pt) 2021-08-17

Family

ID=70774135

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009653-1A BR112021009653A2 (pt) 2018-11-20 2019-08-14 método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico

Country Status (10)

Country Link
US (2) US12220412B2 (https=)
EP (1) EP3883578A4 (https=)
JP (2) JP7472122B2 (https=)
CN (1) CN113329754A (https=)
AU (2) AU2019384074B2 (https=)
BR (1) BR112021009653A2 (https=)
CA (1) CA3120339A1 (https=)
IL (2) IL319327A (https=)
MX (2) MX2021005801A (https=)
WO (1) WO2020106337A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
KR20210141448A (ko) 2018-12-27 2021-11-23 서피스 아프샐믹스 인코포레이티드 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법
SG11202108529WA (en) * 2019-02-08 2021-09-29 Sanofi Sa Biotechnological optimization of microorganisms for the 1,2-dehydrogenation of steroids
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
EP4525983A4 (en) * 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
AU2024348222A1 (en) * 2023-09-27 2026-04-16 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) * 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
AU2003207717B9 (en) 2002-02-01 2009-05-07 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
EP1615647B1 (en) 2003-04-11 2010-01-20 High Point Pharmaceuticals, LLC Pharmaceutical use of fused 1,2,4-triazoles
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
CN1795181A (zh) 2003-05-29 2006-06-28 麦克公司 用作11β－羟基类固醇脱氢酶－1抑制剂的三唑衍生物
US7683059B2 (en) 2003-10-28 2010-03-23 Amgen Inc. Triazole compounds and uses related thereto
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
EP1696915A1 (en) 2003-12-19 2006-09-06 Pfizer, Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
CA2549385A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes
WO2005097759A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
CN101014578B (zh) 2004-09-16 2011-01-19 安斯泰来制药有限公司 三唑衍生物或其盐
US20090093463A1 (en) 2004-11-02 2009-04-09 Agouron Pharmaceuticals Inc. Novel compounds of substituted and unsubtituted adamantyl amides
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
JPWO2006080533A1 (ja) 2005-01-31 2008-06-19 持田製薬株式会社 ３−アミノ−１，２，４−トリアゾール誘導体
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
CA2610903A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
CA2620179C (en) 2005-08-16 2013-10-29 Icagen, Inc. Inhibitors of voltage-gated sodium channels
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
JPWO2007105753A1 (ja) 2006-03-16 2009-07-30 アステラス製薬株式会社 トリアゾール誘導体またはその塩
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
TWI465439B (zh) 2008-07-03 2014-12-21 Astellas Pharma Inc 三氮唑衍生物或其鹽
EP2243494A1 (en) * 2009-04-22 2010-10-27 OntoChem GmbH Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
WO2011068927A2 (en) 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
AU2013231230A1 (en) * 2012-03-13 2014-08-07 AbbVie Deutschland GmbH & Co. KG Method for selecting or identifying a subject for V1B antagonist therapy
EP3166610B1 (en) * 2014-07-09 2022-11-02 Eip Pharma, LLC Methods for treating neurologic disorders
CR20170456A (es) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
WO2023225507A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
EP4525983A4 (en) 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS

Also Published As

Publication number Publication date
US20210393622A1 (en) 2021-12-23
MX2025002836A (es) 2025-04-02
JP7472122B2 (ja) 2024-04-22
CN113329754A (zh) 2021-08-31
US20250205227A1 (en) 2025-06-26
WO2020106337A1 (en) 2020-05-28
AU2025203033A1 (en) 2025-05-22
EP3883578A1 (en) 2021-09-29
JP2022507103A (ja) 2022-01-18
MX2021005801A (es) 2021-08-05
IL283069B2 (en) 2025-09-01
IL283069A (en) 2021-06-30
IL283069B1 (en) 2025-05-01
IL319327A (en) 2025-05-01
JP2024098991A (ja) 2024-07-24
US12220412B2 (en) 2025-02-11
AU2019384074B2 (en) 2025-04-10
AU2019384074A1 (en) 2021-06-03
CA3120339A1 (en) 2020-05-28
EP3883578A4 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
BR112021009653A2 (pt) método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico
US20220249515A1 (en) Ganaxolone for use in treating genetic epileptic disorders
Kundhal et al. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth
CA2640484A1 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
JP2022507103A5 (https=)
CN105358160A (zh) 亚硝酸盐的药物制剂及其用途
JP2022031479A (ja) アルツハイマー病治療に関連するアミロイド関連画像異常の治療または予防方法
KR20130099815A (ko) 글루코코르티코이드에 기초한 조성물의 약량학 및 투여
KR20200062241A (ko) 시포니모드의 투여 요법
JP2019507786A (ja) 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン
US11571412B2 (en) Thromboxane receptor antagonists in AERD/asthma
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
JP2023503928A (ja) 結節性硬化症の治療での使用のためのガナキソロン
JP2019001830A (ja) 医薬
EP4019016A1 (en) Methods of administering intravenous baclofen
BR112021014593A2 (pt) Composições de metilfenidato para tratamento de transtorno de déficit de atenção e hiperatividade
EA051671B1 (ru) Ганаксолон для использования в лечении комплекса туберозного склероза
EA052165B1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]